NYSEAMERICAN:OGEN

Oragenics (OGEN) Stock Forecast, Price & News

$2.91

-0.11 (-3.64%)

(As of 05:25 PM ET)

Compare

Today's Range: $2.85
▼
$3.01
50-Day Range: $2.94
▼
$4.18
52-Week Range: $2.60
▼
$17.40

Volume: 2,463 shs
Average Volume: 14,897 shs
Market Capitalization: $7.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Oragenics (NYSEAMERICAN:OGEN) Stock

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Price History

30 days | 90 days | 365 days | Advanced Chart

OGEN Stock News Headlines

September 21, 2023 | americanbankingnews.com

Oragenics (NYSEAMERICAN:OGEN) Coverage Initiated by Analysts at StockNews.com

September 15, 2023 | americanbankingnews.com

Oragenics (NYSEAMERICAN:OGEN) Now Covered by StockNews.com

September 22, 2023 | MarketBeat Internal (Ad)

MarketBeat's Top 5 Stock Picks - Just Released

MarketBeat has just released five new trading ideas to All Access subscribers, but Tesla, Apple, and Netflix didn't make the cut. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Now, MarketBeat thinks these five stocks may be even better buys.

August 7, 2023 | finance.yahoo.com

Oragenics, Inc. Announces Private Placement

June 5, 2023 | finance.yahoo.com

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

March 29, 2023 | finance.yahoo.com

Oragenics to Participate in the World Vaccine Congress Washington

March 14, 2023 | finance.yahoo.com

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

March 8, 2023 | finance.yahoo.com

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

September 22, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

March 1, 2023 | finance.yahoo.com

Oragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing Pact

March 1, 2023 | finance.yahoo.com

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

February 3, 2023 | financialpost.com

Oragenics, Inc. Regains Compliance with NYSE American

December 23, 2022 | finance.yahoo.com

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

December 22, 2022 | finance.yahoo.com

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

December 20, 2022 | finance.yahoo.com

Oragenics, Inc. Receives NYSE American Notice

December 19, 2022 | financialpost.com

Oragenics, Inc. Announces New Chair

October 24, 2022 | finance.yahoo.com

Oragenics to Participate in the 2022 BioFlorida Annual Conference

September 30, 2022 | benzinga.com

Oral & Dental Probiotics Market Size & Shares by 2027 | Revenue, Cost Analysis, Gross Margins, Future Inv - Benzinga

September 9, 2022 | morningstar.com

Oragenics Inc OGEN Stock Quote

September 7, 2022 | reuters.com

OGEN.P - Oragenics Inc | Stock Price & Latest News | Reuters

August 30, 2022 | reuters.com

OGEN.A - Oragenics Inc | Stock Price & Latest News | Reuters

August 24, 2022 | benzinga.com

Oragenics Announces Preliminary Toxicology Data For Intranasal COVID-19 Vaccine Candidate; Says 'N T-CoV2 - Benzinga

August 24, 2022 | businesswire.com

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate - Business Wire

August 24, 2022 | finance.yahoo.com

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

August 24, 2022 | seekingalpha.com

OGN stock on watch after early toxicology data for intranasal COVID-19 shot (NYSE:OGN) - Seeking Alpha

July 29, 2022 | marketscreener.com

ORAGENICS INC - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. - Marketscreener.com

July 8, 2022 | marketscreener.com

ORAGENICS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

See More Headlines

Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

OGEN Company Calendar

Last Earnings: 8/14/2023
Today: 9/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:OGEN
CUSIP: N/A
CIK: 1174940
Web: www.oragenics.com
Phone: 813-286-7900
Fax: 813-286-7904
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,290,000.00
Net Margins: N/A
Pretax Margin: -10,347.41%
Return on Equity: -128.11%
Return on Assets: -95.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.10
Quick Ratio: 7.10

Sales & Book Value

Annual Sales: $130,000.00
Price / Sales: 56.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.64 per share
Price / Book: 0.52

Miscellaneous

Outstanding Shares: 2,540,000
Free Float: 2,333,000
Market Cap: $7.39 million
Optionable: Not Optionable
Beta: 0.52

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Ms. Kimberly M. Murphy (Age 60)
Pres, CEO & Director
Comp: $550.93k

Dr. Martin Handfield M.Sc. (Age 52)
Ph.D., Chief Scientific Officer
Comp: $264.77k

Ms. Janet Huffman (Age 51)
CFO, Sec. & Treasurer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OGEN Stock - Frequently Asked Questions

How have OGEN shares performed in 2023?: Oragenics' stock was trading at $0.1051 on January 1st, 2023. Since then, OGEN shares have increased by 2,668.8% and is now trading at $2.91.
View the best growth stocks for 2023 here.
Are investors shorting Oragenics?: Oragenics saw a drop in short interest in the month of August. As of August 15th, there was short interest totaling 23,400 shares, a drop of 23.8% from the July 31st total of 30,700 shares. Based on an average trading volume of 10,000 shares, the short-interest ratio is presently 2.3 days. Approximately 1.0% of the company's stock are short sold.
View Oragenics' Short Interest.
How were Oragenics' earnings last quarter?: Oragenics, Inc. (NYSEAMERICAN:OGEN) announced its earnings results on Monday, August, 14th. The biotechnology company reported ($1.51) earnings per share for the quarter. The biotechnology company earned $0.01 million during the quarter.
When did Oragenics' stock split?: Shares of Oragenics reverse split on the morning of Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What other stocks do shareholders of Oragenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Imunon (CLSN), Jaguar Health (JAGX), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV).

What is Oragenics' stock symbol?: Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."
Who are Oragenics' major shareholders?: Oragenics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.65%). Insiders that own company stock include Fred Telling, Joseph Hernandez, Michael O'keefe Sullivan and Robert C Koski.
View institutional ownership trends.
How do I buy shares of Oragenics?: Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Oragenics' stock price today?: One share of OGEN stock can currently be purchased for approximately $2.91.
How much money does Oragenics make?: Oragenics (NYSEAMERICAN:OGEN) has a market capitalization of $7.39 million and generates $130,000.00 in revenue each year.
How can I contact Oragenics?: Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The official website for the company is www.oragenics.com. The biotechnology company can be reached via phone at 813-286-7900, via email at johnm@coreir.com, or via fax at 813-286-7904.

This page (NYSEAMERICAN:OGEN) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial